11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy

Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy

Metabolic oncologic emergencies result from severe electrolyte, mineral, and metabolic derangements triggered by rapid malignant cell turnover or systemic tumor-derived humoral factors. Tumor Lysis Syndrome (TLS) and Hypercalcemia of Malignancy (HCM) represent the two most common metabolic emergencies encountered by Advanced Practice Registered Nurses (APRNs). Prompt identification and aggressive intervention are crucial to prevent acute kidney injury, lethal cardiac dysrhythmias, and mortality.

---

1. Pathophysiology of Tumor Lysis Syndrome

TLS occurs when massive quantities of neoplastic cells lyse rapidly, overwhelming physiological clearance mechanisms and releasing intracellular contents—potassium, phosphorus, and nucleic acids—into the systemic circulation.

Metabolic Cascades

• Hyperuricemia: Purine nucleic acids released from lysed tumor cells are metabolized by xanthine oxidase into uric acid. Uric acid is poorly soluble in acidic tubular fluid, leading to acute uric acid nephropathy, renal tubular precipitation, and obstructive acute kidney injury (AKI).
• Hyperkalemia: Rapid release of intracellular potassium ($K^+$) into extracellular fluid. Represents the most immediately lethal component of TLS, precipitating severe cardiac conduction abnormalities and fatal ventricular dysrhythmias.
• Hyperphosphatemia & Hypocalcemia: Intracellular phosphate concentrations in malignant lymphoblasts are up to 4-fold higher than normal mature lymphocytes. Rapid phosphate release causes hyperphosphatemia, which precipitates with calcium to form calcium-phosphate crystals in renal tubules ($Ca \times P \text{ product } > 60\text{ mg}^2/\text{dL}^2$). Subsequent binding of ionized calcium leads to acute secondary hypocalcemia (tetany, seizures, QTc prolongation).

High-Risk Malignancies

• Burkitt lymphoma, T-cell Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) with high white blood cell count ($>50,000/\mu\text{L}$), bulky High-Grade Non-Hodgkin Lymphoma, and rapidly proliferating solid tumors treated with potent targeted therapies (e.g., venetoclax in CLL).

---

2. Cairo-Bishop Diagnostic Criteria for TLS

The Cairo-Bishop Definition establishes standardized classification for Laboratory TLS (LTLS) and Clinical TLS (CTLS).

Cairo-Bishop Classification Matrix

---

3. TLS Prevention & Management Protocols

TLS Risk Assessment (Malignancy Type, Tumor Bulk, Baseline Renal Function)
  │
  ├─► High Risk (Burkitt, ALL, AML WBC >50k, Bulk >10cm) ──► IV NS 2.5-3.0 L/m²/day + Rasburicase (0.15-0.2 mg/kg)
  ├─► Intermediate Risk (DLBCL, Moderate Bulk) ──────────► IV NS 2.5-3.0 L/m²/day + Allopurinol (300 mg PO QD)
  └─► Low Risk ──────────────────────────────────────────► Oral Hydration + Close Monitoring

Aggressive Intravenous Hydration

• Administer IV 0.9% Normal Saline at $2.5–3.0\text{ L/m}^2/\text{day}$ ($200–300\text{ mL/hr}$) to expand intravascular volume, enhance renal perfusion, and promote continuous flushing of uric acid and calcium-phosphate crystals.
• Target urine output: $\ge 100\text{ mL/m}^2/\text{hr}$ ($\ge 2\text{ mL/kg/hr}$). Note: Exogenous urinary alkalinization (sodium bicarbonate) is no longer recommended due to increased calcium-phosphate crystallization.

Anti-Hyperuricemic Pharmacotherapy

• Allopurinol (Xanthine Oxidase Inhibitor):
  • Dose: 300 mg PO daily (adjust for renal impairment).
  • Mechanism: Blocks conversion of hypoxanthine to xanthine and uric acid. Prevents new uric acid formation but does not clear pre-existing serum uric acid. Used for low-to-intermediate risk TLS prophylaxis.
• Rasburicase (Recombinant Urate Oxidase):
  • Dose: $0.15–0.20\text{ mg/kg}$ IV single dose (or fixed 3–6 mg dose).
  • Mechanism: Enzymatically cleaves existing insoluble uric acid into allantoin, a highly soluble inactive metabolite excreted readily by kidneys. Rapidly lowers uric acid within 4 hours.
  • Indication: High-risk TLS or pre-existing hyperuricemia.
  • CRITICAL CONTRAINDICATION: Strictly contraindicated in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Hydrogen peroxide generated during urate oxidation causes severe methemoglobinemia and fatal hemolytic anemia.
  • Lab Handling: Blood samples for post-rasburicase uric acid testing must be drawn in pre-chilled heparin tubes and immediately immersed in an ice bath to prevent ex vivo degradation of uric acid by rasburicase at room temperature.

Electrolyte Derangement Protocols

• Hyperkalemia: IV Calcium Gluconate (1 g IV over 5 min) for cardiac membrane stabilization, followed by Regular Insulin (10 units IV) + 50% Dextrose (50 mL IV), inhaled Albuterol, loop diuretics, and sodium zirconium cyclosilicate. Initiate emergent hemodialysis if refractory.
• Hyperphosphatemia: Administer oral phosphate binders (sevelamer hydrochloride); restrict dietary phosphate.
• Hypocalcemia: Treat only if clinically symptomatic (tetany, QTc prolongation) using low-dose IV calcium gluconate to avoid accelerating tissue calcium-phosphate precipitation.

---

4. Pathophysiology of Hypercalcemia of Malignancy (HCM)

HCM occurs in up to 30% of cancer patients. It is categorized into four distinct pathophysiological mechanisms:

1. Humoral Hypercalcemia of Malignancy (HHM, ~80%): Tumor secretion of Parathyroid Hormone-related Protein (PTHrP), which binds PTH-1 receptors in bone and kidney, stimulating osteoclast bone resorption and renal tubular calcium reabsorption. Associated with squamous carcinomas (lung, head/neck), renal cell, and breast cancer.
2. Local Osteolytic Hypercalcemia (~20%): Direct osteolytic bone destruction by bone metastases mediated by local RANKL and cytokine release (breast cancer, multiple myeloma).
3. Ectopic 1,25-Dihydroxyvitamin D Production: Overproduction of active calcitriol by malignant lymphocytes in Hodgkin and non-Hodgkin lymphomas.
4. Ectopic Parathyroid Hormone (PTH) Secretion: Rare (<1%).

---

5. HCM Clinical Features & Diagnostic Assessment

Clinical Presentation Matrix

• Renal: Polyuria, polydipsia, nephrogenic diabetes insipidus, acute volume depletion, nephrolithiasis.
• Gastrointestinal: Anorexia, nausea, severe constipation, obstipation, pancreatitis.
• Neurological: Lethargy, confusion, hyporeflexia, muscle weakness, stupor, coma ("psychiatric overtones").
• Cardiovascular: Shortened QTc interval, bradycardia, AV block, digitalis toxicity sensitivity.

Corrected Calcium Calculation

Serum calcium must always be adjusted for hypoalbuminemia: $\text{Corrected Calcium (mg/dL)} = \text{Measured Total Calcium (mg/dL)} + 0.8 \times [4.0 - \text{Serum Albumin (g/dL)}]$

• Severity: Mild ($10.5–11.9\text{ mg/dL}$), Moderate ($12.0–13.9\text{ mg/dL}$), Severe ($\ge 14.0\text{ mg/dL}$ or symptomatic).

---

6. HCM Emergency Management Protocol